Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04626518
Title Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

clear cell renal cell carcinoma

Therapies

MK-4280A

Lenvatinib + Pembrolizumab

Belzutifan + Pembrolizumab

MK-1308A

MK-4830 + Pembrolizumab

Belzutifan + Lenvatinib

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | CAN


No variant requirements are available.